By efrat|2023-09-10T05:56:01+00:00September 10th, 2023|All|Comments Off on Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report
By efrat|2023-09-06T07:40:11+00:00September 6th, 2023|All|Comments Off on Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
By efrat|2023-09-04T09:13:58+00:00September 3rd, 2023|All|Comments Off on Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions
By efrat|2023-08-20T08:11:01+00:00August 26th, 2023|All|Comments Off on Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL
By efrat|2023-08-20T08:11:42+00:00August 14th, 2023|All|Comments Off on Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML
By efrat|2023-08-20T08:12:17+00:00August 14th, 2023|All|Comments Off on Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML
By efrat|2023-08-20T08:13:11+00:00August 6th, 2023|All|Comments Off on Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration
By efrat|2023-08-20T08:13:42+00:00July 30th, 2023|All|Comments Off on Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma
By efrat|2023-08-20T08:15:00+00:00July 24th, 2023|All|Comments Off on July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial
By efrat|2023-08-20T08:16:13+00:00July 16th, 2023|All|Comments Off on July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results